Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report

Abstract

Abstract. The present case report describes a postmenopausal patient with hormone receptor (HR) + /human epidermal growth factor receptor 2 (HER2) + metastatic breast cancer, who experienced progression of disease in bilateral lungs, lymph nodes and the liver under previous endocrine therapy and trastuzumab. Following the failure of two lines of endocrine-based treatment, the patient was administered the combined treatment of everolimus, trastuzumab and exemestane following surgical resection of the liver metastasis. A durable partial remission was achieved, which has continued for >27 months. This prominent clinical outcome in this patient demonstrates that the combined administration of endocrine therapy, trastuzumab and everolimus is clinically effective, and may induce long-term remission in patients with HR + /HER2 + metastatic breast cancer.

Andrographolide and its Attributes Against Triple-Negative Breast Cancer: A Review of the Literature

“…Estrogen, progesterone, and HER2 are the hallmark for the presence of a Breast Tumor, it serves by mimicking the receptors found in the normal breast tissues and sends signals to cells permitting its growth. Nearly 50% of Breast tumors express ER, PR, and HER2 but not in case of the TNBC, in which the expression of the biomarkers is idle 26 . TNBC severity exceeds the positive BC.…”

“…TNBC severity exceeds the positive BC. It has a high risk of re-occurrence and death 20 and can metastasize viscerally to other organs (lymph nodes, bilateral lungs, and the liver) 26 . Metastatic TNBC has a low life expectancy rate and it does not exceed 12 months in spite of the response to chemotherapy 8 .…”